Malignant B lymphocytes from chronic lymphocytic leukemia (CLL) patients maintain the capacity to respond to CD40 ligation, among other microenvironmental stimuli. In this study, we show that (i) leukemic CLL cells stimulated with the soluble form of CD40L in vitro show differential responses in terms of upregulation of surface markers (CD95 and CD80) and induction of chemokines (CCL22 and CCL17) expression/secretion, and that (ii) these changes are mirrored by a distinct activation of intracellular signalling pathways including increase in IKKalpha/beta phosphorylation and upregulation of antiapoptotic proteins (BCL-2 and MCL-1). CLL patients can then be segregated into two distinct functional subsets. We defined the responsive subset of cases CD40L dependent, considering the capacity to respond as a sign of persistent need of this stimulation for the leukemic expansion. Conversely, we named the unresponsive cases CD40L independent, considering them less dependent on this microenvironmental signal, presumably because of a higher autonomous proliferative and survival potential. Importantly, we report that (iii) the two functional subsets show an opposite clinical outcome, with CD40L-independent cases having a shorter time to progression. This indicates that the functional differences observed in vitro may reflect a different leukemic potential in vivo likely responsible for a distinct clinical course.
Malignant B lymphocytes from chronic lymphocytic leukemia (CLL) patients maintain the capacity to respond to CD40 ligation, among other microenvironmental stimuli. In this study, we show that (i) leukemic CLL cells stimulated with the soluble form of CD40L in vitro show differential responses in terms of upregulation of surface markers (CD95 and CD80) and induction of chemokines (CCL22 and CCL17) expression/secretion, and that (ii) these changes are mirrored by a distinct activation of intracellular signalling pathways including increase in
Introduction
Survival and expansion of chronic lymphocytic leukemia (CLL) 1, 2 clones are favored by stimuli originating from the microenvironment. 2 The stimulation through the B-cell receptor has been found to be a key factor, 3, 4 although the response to B-cell receptor stimulation is heterogeneous and only in a subset of patients the malignant cells are responsive in vitro to the immunoglobulin (Ig) crosslinking that leads to an effective cell activation. 5, 6 CLL cases unresponsive to Ig ligation show the functional and biochemical features of B cells anergized by an in vivo antigen (Ag) encounter and a have a better clinical outcome 5, 7 as compared with CLL cases responsive to anti-IgM who have a poorer clinical outcome and tend to express other negative prognostic factors (for example, ZAP70 or CD38 positivity, absence of IGHV gene mutations). 6, [8] [9] [10] There is substantial evidence that CLL cells retain the capacity to respond in vitro also to the so-called 'second signal' delivered through CD40, 11 a member of the tumor necrosis factor receptor family. In normal B cells stimulation by CD40-ligand (CD40L/ CD154), the cognate ligand expressed on activated T lymphocytes, 12 occurs on Ag recognition and is crucial to initiate the processes of B-cell proliferation and differentiation. 13, 14 In vitro CD40 stimulation can rescue CLL cells from apoptosis and/or induce their proliferation; [15] [16] [17] [18] [19] it modulates the expression of surface molecules (for example, CD80; CD95) [19] [20] [21] and of apoptosis-regulatory proteins such as BCL-2, survivin, 17 BCL-X or MCL-1 (refs 20-22) and the secretion of the chemoattractants CCL22 (MDC) and CCL17 (TARC). 23 Conceivably, CD40 stimulation may occur also in vivo as CD4 þ CD40L þ T cells are invariably present in infiltrated lymph nodes and bone marrow 1, 24 and tend to concentrate within tissue proliferation centers where proliferating malignant B cells cluster around them. 25 The engagement of CD40 by CD40L induces activation of both the canonical and non-canonical nuclear factor kB (NF-kB) signalling pathways. 26 The activation of the canonical NF-kB pathway leads to the phosphorylation of the IKK complex including IKK alpha and IKK beta; the activation of non-canonical NF-kB signalling pathway involves specifically IKK alpha. Therefore, it is possible to analyze the phosphorylation status of IKK kinases as a read-out of NF-kB signalling pathways activation. 27 Not all CLL clones respond to CD40 stimulation in vitro, indicating a clonal functional heterogeneity. 1, 17, 18 This is relevant considering that CD40 has attracted great interest as a potential therapeutic target in CLL, 28, 29 and in ongoing clinical trials either activation of CD40 by genetically modified leukemic cells expressing CD40L gene 30 or CD40 inhibition with anti-CD40 antagonist antibody 31 are used in different therapeutic strategies. In this work, we have identified two distinct subsets of CLL patients, which we have named CD40L dependent and CD40L independent, based on the in vitro cell response to CD40 stimulation in terms of upregulation of surface molecules (CD95 and CD80), induction of chemokine expression (CCL22 and CCL17) or secretion (CCL22), as well as upregulation of antiapoptotic molecules (BCL-2 and MCL-1) and increased phosphorylation of signalling molecules (IKK alpha/beta). Interestingly, CD40L-independent cases had a significantly worse clinical progression as compared with CD40L-dependent CLL.
Methods

Patients
Leukemic lymphocytes were obtained from the peripheral blood of 60 unselected CLL patients, diagnosed according to the international guidelines. 32 All tissue samples were obtained with approval of the institutional review board of San Raffaele Scientific Institute (Milan, Italy). A total of 37 patients were untreated at the time of the analysis among which eight cases progressed between 16 and 217 months (median time to progression 61 months) after diagnosis. The remaining 29 remained stable for a median followup of 62 months. Another 20 cases were studied after the first progression and were off therapy for at least 6 months before the beginning of the study. Three patients were lost to follow-up. The following parameters were analyzed for each patient: age, disease stage at diagnosis according to Binet 33 or modified Rai criteria,
34
CD38 expression, 35 IGHV gene mutational status, 36 ZAP-70 expression, 9 characterization of disease as progressive or stable as defined by the IWCLL-NCIWG. 32 
Cell purification and in vitro CD40 stimulation
Mononuclear cells from all cases were isolated after Ficoll gradient, and in a pilot series of 14 cases CD19
þ leukemic B cells were also purified using a B lymphocyte-enrichment kit (RosetteSep; StemCell Technologies, Peschiera Borromeo, Milan, Italy) and immediately used for the experiments depicted below. Purity of all preparations was always above 99% and the cells co-expressed CD19 and CD5 on their cell surfaces, as checked by flow cytometry (FC500; Beckman Coulter, Cassina De Pecchi, Milan, Italy); preparations were virtually devoid of NK, T lymphocytes and monocytes.
Total peripheral blood mononuclear cells and purified B lymphocytes were resuspended in RPMI 1640 medium (Life Technologies, San Giuliano Milanese, Milan, Italy), containing 10% fetal calf serum, 2 mM L-glutamine and 15 mg/ml gentamicin, and cultured for up to 3 days with or without soluble recombinant human CD40L (sCD40L) at 100 ng/ml plus 1 mg/ml of enhancer, according to the manufacturer's instructions (Alexis Corporation, San Diego, CA, USA).
Cells were collected at different time points, for flowcytometryic analysis (24 and 72 h), western blotting experiments (5 and 30 min for IKK and 24 and 72 h for BCL-2 and MCL-1), and RNA extraction (24 and 72 h). At each time point, culture supernatants were collected, filtered and stored at À80 1C for enzyme-linked immunosorbent assays (ELISA).
Cytometric analyis
At 24 and 72 h, cultured cells were analyzed with a FC500 cytometer (Beckman Coulter), acquiring at least 10 000 events and using the following monoclonal antibodies: anti-CD19, anti-CD20, anti-CD5, anti-CD38, anti-CD80 (Becton and Dickinson, San Jose, CA, USA), anti-CD95 (Caltag Laboratories San Francisco, CA, USA) 37 and ZAP70 expression was analyzed using the anti-ZAP70 antibody (Caltag, Burlingame, CA, USA) as previously described. 38 In parallel, cell viability was also assessed using the Annexin V-based apoptosis detection kit (R&D Systems, Flanders, NJ, USA).
RNA extraction and PCR
After 24 and 72 h of culture, total RNA was extracted from 3 Â 10 6 cells using Trizol (Invitrogen life technologies, Paisley, UK), following the manufacturer's instructions. Complementary DNA synthesis and PCR amplifications were carried out as described. 39 
Cell lysis and western blot analysis
After 5 and 30 min, 24 and 72 h of culture, 3 Â 10 6 were pelleted, resuspended in cold lysis buffer (150 mM NaCl, 1% NP40, 50 mM TrisHCl, 1 mM EDTA, protease inhibitors and phosphatase inhibitors) and spinned in microcentrifuge at 4 1C for 20 min at 13 000 r.p.m.; lysate was recovered from supernatant and immediately used for western blotting or frozen at À20 1C.
Whole-protein extracts from either fresh or thawed lysates were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and proteins from gel were electron transferred onto nitrocellulose membranes, and probed with anti-BCL2 (Upstate Biotechnology, Billerica, MA, USA), anti-MCL-1, anti-IKK alpha/beta (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-phospho-IKK alpha/beta (Cell Signaling, Denvers, MA, USA) or anti-beta-Actin (Sigma, St Louis, MO, USA) antibodies. Immunoreactivity was revealed by incubation with either goat anti-rabbit Ig, goat anti-mouse Ig (Upstate Biotechnology) conjugated with HRP, followed by ECL reaction (Pierce, Waltham, MA, USA) and film exposure. Densitometric analysis of protein-specific bands was performed using ImageQuant Software (GE Healthcare, Upsala, Sweden). CLL MEC1 cell line was used as positive control. 40 
Enzyme-linked immunosorbent assay
The presence of the chemokines CCL17 and CCL22 in the supernatants from both untreated and CD40L-treated cells, cultured for 72 h, was detected and quantified by ELISA using commercially available kits (R&D Systems, Minneapolis, MN, USA). The lower limit of detection of the ELISA was 0.25 ng/ml for CCL22 and 0.13 ng/ml for CCL17.
Statistical analysis
Patients were grouped in two subsets (CD40L dependent and CD40L independent) according to their in vitro response to sCD40L stimulation. Parametrical and non-parametrical data were compared with the functional response ( Table 1) . For nonparametrical data, w 2 test and Fisher exact test defined the statistical significance (two-tales) of the contingency tables. For parametrical data the analysis of variance test was used (Table 1) . Time to progression (TTP) was calculated from diagnosis to first occurrence of progression according to IWCLL-NCI-WG criteria. 32 TTP curves were plotted according to Kaplan-Meier method and compared with the log-rank test. A correlation was considered as statistically significant when the P value of the corresponding test was not greater than 5%. All statistical computations were conducted using SPSS version 16.0 (SPSS, Chicago, IL, USA). Statistical analysis of western blot data was performed using Student's t-test.
Results
CLL cells show a heterogeneous response to CD40L stimulation
We cultured CLL B cells for up to 3 days in the presence of sCD40L and we evaluated changes in the expression of different molecules at protein and RNA level.
First, we analyzed by flow cytometry the surface expression of the activation markers CD95 and CD80 that are upregulated following CD40 stimulation of normal B cells. 21 At basal level, CD95 expression was absent in 59/60 CLL cases, while CD80 was detected in 27/60 cases (45%). After CD40 stimulation, malignant cells from 34/60 patients (56.7%) showed the induction of CD95 and/or the upregulation of CD80 expression ( Figure 1a ). In addition, the same cases showed also an increase in cell viability of 26 ± 9% as compared with control cultures (data not shown). 18 Next, we evaluated the expression and secretion of the chemokines CCL22 and CCL17 in response to CD40 ligation in 46 patients. Although by reverse-transcription PCR we observed a significant increase in gene expression only for CCL17 (Figure 1b ) (27/46) , in all these cases the secretion of both chemokines was actually increased as detected by ELISA (Figure 1c) .
In 27/46 (58.7%) cases we observed a concomitant functional response after CD40 stimulation with all the four assays utilized (cytofluorimetric analysis, reverse-transcription PCR assay for CCL17, ELISA for CCL22 and ELISA for CCL17). On the basis of these results we defined these cases CD40L dependent. The remaining 21 patients (45.7%) did not show any phenotypic and functional modifications after in vitro CD40 stimulation (14 cases) or had marginal changes in only one of the four assays (one CD80/CD95 upregulation, one induction of a PCR band for CCL17, six positive ELISA assays for CCL22). All these cases were defined CD40L independent.
To exclude that T, NK and monocytes cells could affect CD40L differential response in vitro, we performed parallel stimulation experiments using unfractioned peripheral blood mononuclear cells and purified leukemic B cells from 14 cases (seven dependent and seven independent). We did not observe any differences in terms of response confirming, as expected, the cell specificity of the stimulation through CD40 receptor (data not shown).
A biochemical signature for CD40 response
On the basis of these results, we aimed at defining biochemical features that might correlate with the different functional response and help distinguishing the two subsets of patients. This set of experiments was performed only on purified leukemic B cells (99% pure) from the peripheral blood of CLL patients, after culture in the presence or the absence of sCD40L.
CD40L response was evaluated in 12 CLL samples (six CD40L dependent and six CD40L independent) at early time points (5 and 30 min after stimulation) by analyzing the phosphorylation status of IKK alpha/beta by western blotting. As shown in Figure 2a , only CD40L-dependent patients (6/6) showed a significant upregulation of phospho-IKK alpha/beta as compared with the untreated samples, while CD40L-independent patients (6/6), (Figure 2a) , showed no significant enhancement in IKK alpha/beta phosphorylation (see Figure 2b for comparison between the two subsets). In addition, we observed that the basal levels of IKK alpha/beta phosphorylation are different among the two groups, with CD40L-independent cases showing a higher level of basal activation (P ¼ 0.0279) (Figure 2c ). We then evaluated by western blotting the levels of protein expression at later time points (24 and 72 h) after sCD40L treatment, focusing our attention on the antiapoptotic molecules BCL-2 and MCL-1. We tested BCL-2 expression in six CD40L-dependent and six CD40L-independent cases and we observed that the level of the protein in cells from CD40L-dependent patients was significantly upregulated (P ¼ 0.04) in contrast to CD40L-independent samples (Figures 3a and b) . Interestingly, the analysis of 23 further CLL patients (11 CD40L independent and 12 CD40L dependent) for BCL-2 expression at basal level showed that the levels of expression before stimulation were associated with the capacity to respond to CD40L stimulation in vitro (P ¼ 0.0019) (densitometric analysis Figure 3c ) suggesting that the expression of this antiapoptotic molecule may depend on a similar stimulation also in vivo.
Finally, in four patients (two CD40L dependent and two CD40L-independent), we also evaluated MCL-1 expression, and similarly to BCL-2, we observed a significant protein increase Response to CD40 ligation in CLL C Scielzo et al only in the CD40L-dependent cases at both 24 and 72 h as compared with controls (Figures 3d and e) .
Clinical correlations
To assess whether the observed functional difference might have clinical implications, we retrospectively correlated several clinical parameters (Table 1) with the in vitro response to CD40 ligation. CD40L-dependent cases had a lower mean lymphocyte count in peripheral blood in comparison with CD40L independent (34 660/ml vs 65 010/ml, P ¼ 0.012, at the time of analysis while hemoglobin, platelet and b2-microglobulin values were similar in both groups. Although the differences between the two groups in terms of disease progression and need for treatment did not reach statistical significance (P ¼ 0.067 and P ¼ 0.064, respectively), TTP curves showed a clear advantage for CD40L-dependent patients, who had a median TTP of 168 months compared with the 78 months of CD40L independent (P ¼ 0.041) (Figure 4) . A significant association was observed only with ZAP70 expression (P ¼ 0.0037) among the major prognostic markers (CD38, IGHV gene mutations, see Table 1 ). Interestingly, when we analyzed the CD38-positive subgroup (16 patients), the response to CD40 ligation was able to further subdivide these patients in terms of clinical outcome and prognosis (Figure 4b ). In this patient sub-population all CD40L-independent cases had a progressive disease (5/5, 100%), while the majority of CD40L-dependent cases (8/11, 72.7%) had a stable disease (P ¼ 0.026). Among CD38 þ cases, TTP was also significantly shorter in CD40L-independent patients (20 months vs 130 months, P ¼ 0.001).
Discussion
CD40/CD40L interactions are crucial for maturation, expansion and survival of normal B lymphocytes. Malignant B cells make no exception as leukemic CLL B cells maintain the capacity to respond to several microenvironmental stimuli including CD40 ligation. 25 Here we show that (i) CLL B cell clones may show different responses in terms of upregulation of surface markers of activation (CD95 and CD80) and induction of chemokines (CCL22 and CCL17) expression/secretion and that (ii) these changes are mirrored by a distinct activation of intracellular signalling pathways including increase in IKK alpha/beta phosphorylation as well as an upregulation of antiapoptotic proteins (BCL-2 and MCL-1). Based on the level of activation achieved by leukemic B cells when stimulated with the soluble form of CD40L in vitro, CLL patients can segregate into two distinct functional subsets. We defined the responsive subset of cases CD40L dependent, considering the capacity to respond as a sign of persistent need of this stimulation that is available in vivo for the leukemic clonal expansion. 41 Conversely, we named the unresponsive cases CD40L independent, considering them less dependent on this microenvironmental signal, presumably because of a higher autonomous proliferative and survival potential. The relevant observation is that the two distinct functional subsets show an opposite clinical outcome, with CD40L-independent cases having a shorter TTP (Figure 4a ; Table 1 ). This indicates that the functional differences observed in vitro may reflect a different leukemic potential in vivo that may be responsible for a distinct clinical course.
Such heterogeneity of response has not been observed when CD40L was used to increase immunogenicity of CLL cells, by stably transducing CD40L either in stromal cells 42 or directly in CLL cells 30, 43 to crosslink CD40 on transduced and nontransduced bystander CLL cells. Conceivably, the strength of the signal delivered to the leukemic cells was higher than that provided by the soluble form of CD40L that we have used in this work. The high levels of expression achieved after transduction of molecules in a membrane-bound form likely produce a much stronger effect that, although beneficial when the purpose is to increase the leukemic cells immunogenicity, could not adequately represent the currently unknown intensity of the signal occurring in vivo. Along the same line of reasoning, we have previously reported that the use of 10 times higher concentrations of soluble CD40L could indeed obtain a response from all cases, although the level of response in terms of cellular modifications was still different in different subsets of patients. 44 We have observed a significant correlation between the type of response to CD40 ligation (dependent vs independent) and the clinical parameters of poor outcome, including ZAP70 expression, while we were unable to find any correlation with other classical 'biological' prognostic markers like CD38 expression 35 or IGHV gene mutational status 36 as one might have expected. Recently, correlations between functional features of CD40 ligation and IGHV gene mutational status have been reported in some instances. 42, 45 This discrepancy could be simply explained by the different number of cases tested and/or by differences in the experimental models used, as CD40 stimulation was studied together with additional stimuli like cytokines 45 or Toll-like receptors ligands. 42 A final answer will be only obtained with a prospective study involving hundreds of cases to eliminate any selection bias. Such a study will also help elucidating whether the capacity to respond to CD40 stimulation remains stable over time and can predict the outcome at any given moment during the disease course or whether it modifies indicating a functional switch that may herald a clinical turning point.
It is known that poor prognosis cases (generally defined by, but not limited to, IGVH unmutated cases, ZAP70 þ or CD38 þ cases or cases expressing specific stereotyped receptors) tend to maintain the capacity to be stimulated through the B-cell receptor usually being induced to enter the cell cycle. In contrast, we here show that poor prognosis cases do not likely respond to CD40 ligation, suggesting the independence from the need of a classic T-cell help. This is also in keeping with previous experimental evidences where stimulation with CpG-DNA showed a heterogeneous response in CLL cells with the progressive ones being induced to proliferate. 46, 47 This dual B-cell receptor-Toll-like receptor engagement (in the absence of CD40 stimulation) is reminiscent of the classical model of thymus-independent type I antibody responses in autoimmune disorders 48 and could then be hypothesized to occur also in the natural history of at least a subset of CLL, especially with progressive disease.
Along the same line, we were able to show that the response to sCD40L significantly discriminated the clinical outcome among CD38 þ patients (Figure 4b ), with 8/11 CD38 þ , CD40L-dependent patients being stable while all (5/5) CD38 þ , CD40L-independent progressed (P ¼ 0.0026). Response to CD40 ligation in CLL C Scielzo et al
In conclusion, based on in vitro cellular and biochemical responses following ligation with soluble CD40 ligand, we have identified two distinct subsets of CLL patients (named CD40L dependent and CD40L independent). Interestingly, CD40L-independent cases had a worse clinical outcome as compared with CD40L-dependent CLL, in terms of clinical progression. The existence of two distinct functional subsets that correlate with a distinct outcome, confirm the role of the microenvironment and its stimuli in the natural history of CLL, where the activation of selected intracellular pathways may become responsible for specific disease courses.
